Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF

LONDON, July 18, 2016 /PRNewswire/ --

A new report by DART Markets forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $17.38bn in 2020. That revenue forecast and others appear in Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF, published in July 2016.

This 208-page report provides quantitative and qualitative information on 10-years revenue forecasts to 2026 at overall world market, disease submarkets, product (brand) and national market level presented in 121 charts and discussion. The study gives revenue predictions to 2026 for four therapeutic submarkets at world level:

• Wet age-related macular degeneration (wAMD) 
• Dry AMD (dAMD) 
• Diabetic retinopathy (DR) 
• Other retinal diseases (grouped forecast). 

The study also provides revenues and forecast of five prominent drugs to 2026:

• Lucentis 
• Eylea 
• Avastin 
• Visudyne 
• Jetrea 

This report discusses the competitive landscape in the retinal diseases drugs market, which includes discussion on SWOT, STEP, Leading Companies, and M&A activities in this market.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Research, data and analyses cover activities of leading companies in the retinal diseases drugs industry:

• Roche 
• Novartis 
• Bayer 
• Regeneron 
• Allergan 
• Valeant 
• Other manufacturers and marketers of ophthalmic pharmaceuticals 

This new study also discusses leading pipeline candidates for Wet AMD, Dry AMD, and Diabetic Retinopathy, shows two interviews and predicts revenues to 2026 in 11 leading national markets.

The work analyses these national markets:

• US 
• Japan 
• EU5 (Italy, Spain, Germany, the UK and France) 
• BRIC (Brazil, Russia, India and China) 
• Rest of the World 

This report also provides a separate chapter on Pricing, Reimbursement, Market Access and Regulations, providing insights on these national markets:

• US 
• Japan 
• EU5 
• Emerging Markets 

Table of Contents 

CHAPTER 1: EXECUTIVE SUMMARY 

1.1 Report Description

1.2 Questions Answered by This Report

1.3 What This Report Provides

1.4 Research Methodology

CHAPTER 2: DISEASE AND MARKET OVERVIEW 

2.1 Epidemiology of Retinal Diseases?

2.2 Diagnostics and Guidelines

2.3 Retinal Diseases- Current Treatment Options

CHAPTER 3: COMPETITIVE LANDSCAPE - RETINAL DISEASES DRUGS INDUSTRY 

3.1 STEP Analysis: Social, Technological, Economic and Political Factors Affecting the Retinal Diseases Industry and Market.

3.1.1 Social

3.1.2 Technological

3.1.3 Economic

3.1.4 Political

3.2 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Retinal Diseases Market

3.2.1 Strengths

3.2.2 Weaknesses

3.2.3 Opportunities

3.2.4 Threats

3.3 Leading Companies in Retinal Diseases Market

3.3.1 Regeneron- Leading the Market with Eylea

3.3.1.1 Regeneron- Revenue Performance Analysis, 2015

3.3.1.2 Regeneron (Eylea) - Revenue Performance, 2015

3.3.2 Novartis- Pushed Down to Second Position

3.3.2.1 Novartis- Revenue Performance Analysis, 2015

3.3.2.2 Novartis (Lucentis) - Revenue Performance, 2015

3.3.3 Roche

3.3.3.1 Roche- Revenue performance Analysis, 2015

3.3.3.2 Roche (Lucentis and Avastin) - Revenue Performance, 2015

3.3.4 Bayer

3.3.4.1 Bayer- Revenue performance Analysis, 2015

3.3.4.2 Bayer (Eylea) - Revenue Performance, 2015

3.4 Mergers & Acquisitions in Retinal Diseases Drugs Industry, 2015

CHAPTER 4: GLOBAL MARKET SEGMENTATION-WET AMD SUBMARKET 

4.1 Wet AMD Market, 2015

4.2 Wet AMD Drugs: Market Forecast 2016-2026

4.3 Porter's Five Forces Analysis for Retinal Drug Industry

4.4 Eylea: Leading Drug in the Market

4.4.1 Revenue Continuosly Increasing in Past Years

4.4.2 Is lucentis Inferior to Eylea?

4.4.3 Has Eylea Already Achieved Maximum Profit Making Point?

4.4.4 New Indications Approval for Eylea

4.4.5 Eylea Revenue Forecast 2015-2026

4.5 Lucentis: Reached Second Position in line

4.5.1 Lucentis Acheieved Maximum Revenue in Past

4.5.2 Avastin Hurdle for Lucentis Growth

4.5.3 Lucentis Failed to Show Superiority to Avastin

4.5.4 Lucentis Moves Into DME and Beyond

4.5.5 Improving Cost and Compliance for Lucentis

4.5.6 Lucentis Revenue Forecast 2015-2026

4.5.7 Will Controversies Affect Lucentis' Growth?

4.6 Avastin: Leader in the Market by Volume

4.6.1 Past Revenue in wet AMD: Increasing Use of Avastin

4.6.2 Judicial Review for Price Adjustment

4.6.3 Roche Effort's to Block Off-Label Use of Avastin

4.6.4 CATT study challenged by Roche and Novartis

4.6.5 Will Avastin be affected by Eylea in the Market?

4.6.6 Avastin Revenue Forecast, 2015-2026

4.6.7 Avastin has Central Position in the Market

4.7 Visudyne: Declining Sales throughout

4.7.1 Visudyne Revenue Forecast, 2015-2026

4.8 Jetrea: Disappointing Launch in 2013

4.8.1 Jetrea Revenue Forecast, 2015-2026

CHAPTER 5: GLOBAL MARKET SEGMENTATION- DRY AMD SUBMARKET  

5.1 Dry AMD Market, 2015

5.2 Dry AMD Drugs: Market Forecast 2016-2026

CHAPTER 6: GLOBAL MARKET SEGMENTATION- DIABETIC RETINOPATHY SUBMARKET 

6.1 Diabetic Retinopathy Market, 2015

6.2 Diabetic Retinopathy Drugs: Market Forecast 2016-2026

CHAPTER 7: RETINAL DISEASES DRUGS: WORLD INDUSTRY 

7.1 Retinal Diseases Market Overview

7.2 Retinal Diseases-Market Segmentation

7.3 Retinal Diseases Market Forecast, 2016-2026

7.4 Eylea Became the Leader in the Market

7.5 Regeneron- Leading Company in the Market

7.6 Significant Disease Areas for the Market

7.7 Drivers and Restraints for Retinal Diseases market

CHAPTER 8: RETINAL DISEASES DRUGS INDUSTRY REVENUE, BY GEOGRAPHY 

8.1 National Market Overview: The US Dominates in 2015

8.2 Regional Retinal Disease Market Forecast: 2016-2026

8.3 The US: Leading Market for Retinal Diseases

8.3.1 The US Market Forecast 2016-2026

8.3.2 STEP Analysis for the US Market

8.4 Japan: Strong Market Potential

8.4.1 Japan Market Forecast 2016-2026

8.4.2 STEP Analysis for Japan Market

8.5 EU5: Ageing Populations to Drive Market Growth

8.5.1 EU5 Market Forecast 2016-2026

8.5.2 Germany Market Forecast 2016-2026

8.5.3 France Market Forecast 2016-2026

8.5.4 Italy Market Forecast 2016-2026

8.5.5 UK Market Forecast 2016-2026

8.5.6 Spain Market Forecast 2016-2026

8.5.7 STEP Analysis for EU5 Market

8.6 BRIC Nations: The Biggest Growth Driver for the Market

8.6.1 BRIC Market Forecast 2016-2026

8.6.2 China Market Forecast 2016-2026

8.6.3 India Market Forecast 2016-2026

8.6.4 Brazil Market Forecast 2016-2026

8.6.5 Russia Market Forecast 2016-2026

8.6.6 STEP Analysis for BRIC Market

CHAPTER 9: RETINAL DISEASES R&D PIPELINE REVIEW 

9.1 The Leading Pipeline Candidates for Wet AMD

9.2 Fovista (Ophthotech Corporation/Novartis): Waiting to Hit the Market

9.2.1 Results for Three Phase 3 Trials to be Declared Soon

9.2.2 New Move towards Combination Therapies

9.2.3 Ophthotech Public Effort for Phase 3

9.3 Conbercept (Chengdu Kanghong Biotech): Another Phase 3 Candidate

9.4 Other Growth Factor Targets in the Pipeline

9.4.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop

9.4.2 VEGF and PDGF Target for Allergan and Molecular Partners

9.4.3 iSONEP (Lpath): Collaboration with Pfizer

9.4.4 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options

9.5 Is There a Need for New Anti-VEGFR Agents or Delivery Systems?

9.5.1 Abicipar Pegol (Allergan): Novel Protein

9.5.2 Brolucizumab (Alcon): Single- Chain Fv Fragment

9.5.3 PDS 1.0 (ForSight Vision4): New Delivery System for Lucentis

9.5.4 NT-503 (Neurotech): Improved Delivery Platform

9.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop

9.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way

9.6 Novel Delivery Systems to Revitalize Anti-Inflammatory Approaches

9.7 Other Targets in wet AMD Drug Development

9.7.1 Kinase Inhibitors: Any success in wet AMD?

9.7.2 Factor C5: A More Promising Target

9.7.3 Integrins: Scope for Another VEGF Blockage Path?

9.7.4 Jetrea (ThromboGenics/Novartis): Will it Help wet AMD Patients?

9.7.5 Novel Treatments Targeting Angeogenisis

9.8 Regenerative Medicine Approaches

9.9 Pipeline for Dry AMD Segment, 2015-2026

9.10 MC-1101 (MacuCLEAR): Leading the pipeline

9.11 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3

9.12 High Hopes for Complement Inhibition in Dry AMD

9.12.1 Lampalizumab (Roche): Is it a major Breakthrough?

9.13 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis

9.14 Neuroprotection: One of Modern Medicine's Holy Grails

9.14.1 Tandospirone (Alcon): Not effective in GA

9.14.2 Renexsus (Neurotech): Hoping for Positive Results

9.14.3 Novadur (Allergan): Longer Duration of Action

9.14.4 VAR10200 (Varinel): A Preclinical Candidate to Watch

9.15 Regenerative Medicine for Dry AMD Treatment

9.15.1 Gene Therapies Less Prominent Than Stem Cells in Dry AMD

9.15.2 OpRegen (Biotime): Leader in Stem Cells

9.15.3 MA09-hRPE Cellular Therapy (Ocata Therapeutics)

9.15.4 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space

9.15.5 Stemedyne-RPE (Stemedica Cell Technologies)

9.15.6 First iPSC Trial in Japan in Dry AMD Patients

9.16 Other Treatments for Dry AMD

9.17 Pipeline for Diabetic Retinopathy Segment, 2015-2026

9.17.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population

9.17.2 Lucentis: The Game Changer for DR?

9.17.3 New Anti-VEGF Additions

9.18 Steroids in Development for DR

9.19 Other Products in Development for DR

9.19.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation

9.19.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?

9.19.3 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013

9.19.4 Jetrea (ThromboGenics/Novartis): Possibilities in DME?

CHAPTER 10: PRICING, REIMBURSEMENT AND MARKET ACCESS 

10.1 Regulatory Hurdles and Update on Regulations - Retinal Diseases Drugs Market

10.1.1 US

10.1.2 Japan

10.1.3 EU5

10.1.4 Emerging Markets

10.2 Pricing, Reimbursement and Market Access - Retinal Diseases Drugs Market

10.2.1 US

10.2.2 Japan

10.2.3 EU5

10.2.4 Emerging Markets

CHAPTER 11: EXPERT OPINIONS 

11.1 Interview with Ms. Cathy Yelf, CEO, Macular Society, UK

11.2 Interview with Dr. Ken Green, Senior Vice President and Chief Scientific Officer, Alimera Sciences, Inc.

CHAPTER 12: RETINAL DISEASES DRUGS MARKET CONCLUSIONS AND RECOMMENDATIONS FOR BUSINESS STRATEGIES 

12.1 Eylea Taken Over Lucentis Market

12.2 Three Competitors for Anti-VEGF Market

12.3 Wet AMD Drugs Expanding to Other Indications

12.4 Extensive Opportunities in Dry AMD Market

12.5 Fovista To Launch Soon With High Expectations

12.6 Retinal Diseases Holds the Largest Area of Ophthalmics

12.7 Recommendation: Opportunities Available in the Market

APPENDIX

DART Report Evaluation Form

LIST OF FIGURES 

Figure 1: AMD and Other Retinal Diseases Drug Market Share (%), 2015

Figure 2: STEP Analysis for Retinal Diseases Market, 2016-2026

Figure 3: SWOT analysis of Retinal Diseases Market, 2016-2026

Figure 4: Regeneron Historical Revenue ($bn), 2011-2015

Figure 5: Novartis Historical Revenue ($bn), 2011-2015

Figure 6: Novartis Revenue Share (%) by Segment, 2015

Figure 7: Roche Historical Revenue ($bn), 2011-2015

Figure 8: Roche Revenue Share (%) by Segment, 2015

Figure 9: Bayer's Pharmaceutical Segment Historical Revenue ($bn), 2011-2015

Figure 10: Market Breakdown by Product Market Share (%), 2020

Figure 11: Market Breakdown by Product: Market Share (%), 2026

Figure 12: Market Forecast by Product: Revenue ($bn), 2015-2026

Figure 13: Market Breakdown by Product: Revenue ($bn), 2015, 2020 and 2026

Figure 14: Wet AMD Segment Forecast Revenue ($bn), 2015-2026

Figure 15: Porter's Five Forces Analysis for Drugs, 2015

Figure 16: Eylea Forecast Revenue ($bn), 2015-2026

Figure 17: Lucentis Forecast Revenue ($bn), 2015-2026

Figure 18: Avastin Forecast Revenue ($bn), 2015-2026

Figure 19: Visudyne Forecast Revenue ($bn), 2015-2026

Figure 20: Jetrea Forecast Revenue ($bn), 2015-2026

Figure 21: Dry AMD Segment Forecast Revenue ($bn), 2015-2026

Figure 22: DR Segment Forecast Revenue ($bn), 2015-2026

Figure 23: World AMD and Other Retinal Diseases Market Forecast Revenue ($bn), 2015-2026

Figure 24: Market Breakdown by Disease Segment Revenues ($bn), 2015

Figure 25: Market Breakdown by Disease Segment Market Share (%), 2015

Figure 26: Retinal Diseases Market Breakdown by Segment Revenue ($bn), 2015, 2020 and 2026

Figure 27: Retinal Diseases Market Breakdown by Segment Revenue ($bn), 2015-2026

Figure 28: Market Breakdown by Disease Segment Market Share (%), 2020

Figure 29: Market Breakdown by Disease Segment Market Share (%), 2026

Figure 30: Market Breakdown by Products Revenue ($bn), Market Share (%), 2015

Figure 31: Market Breakdown by Company Market Share (%), 2015

Figure 32: Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010

Figure 33: Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010

Figure 34: The National Market Share (%) of Retinal Diseases, 2015

Figure 35: Regional Market Breakdown Revenue ($bn), 2015, 2020 and 2026

Figure 36: The National Market Share (%) of Retinal Diseases, 2020

Figure 37: The National Market Share (%) of Retinal Diseases, 2026

Figure 38: US Retinal Diseases Market Forecast Revenue ($bn), 2015-2026

Figure 39: STEP Analysis for Retinal Diseases Market in the US, 2016-2026

Figure 40: Japan Retinal Diseases Market Forecast Revenue ($bn), 2015-2026

Figure 41: STEP Analysis for Retinal Diseases Market in Japan, 2016-2026

Figure 42: EU5 Retinal Diseases Market Share (%) Forecast, 2015, 2020 and 2026

Figure 43: EU5 Retinal Diseases Market Forecast Revenue ($bn), 2015-2026

Figure 44: Germany Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 45: France Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 46: Italy Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 47: UK Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 48: Spain Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 49: STEP Analysis for Retinal Diseases Market in EU5, 2016-2026

Figure 50: BRIC Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 51: BRIC Retinal Diseases Market Share (%) Forecast, 2015, 2020 and 2026

Figure 52: China Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 53: India Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 54: Brazil Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 55: Russia Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Figure 56: STEP Analysis for Retinal Diseases Market in BRIC, 2016-2026

Figure 57: Healthcare Expenditure and GDP For Countries, 2013

Figure 58: National Market CAGR (%), 2015-2026

Figure 59: Retinal Diseases Drugs Revenue ($bn), 2015

Figure 60: Retinal Market Segments CAGR (%), 2015-2026

LIST OF TABLES 

Table 1:  World AMD and Other Retinal Diseases Market Revenue ($bn) Forecast, 2015-2026

Table 2: Bayer Pharmaceutical Segment Revenue ($bn) by Region, 2014 and 2015

Table 3: Types of CNV in Wet AMD: Approximate Proportion of Cases (%), 2014

Table 4: Retinal Diseases Drug Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026

Table 5: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2020

Table 6: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2026

Table 7: Wet AMD Segment Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 8: Wet AMD Segment Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 9: Eylea Historical Revenue ($bn), AGR (%), 2012-2015

Table 10: Eylea Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 11: Eylea Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 12: Lucentis Historical Revenue ($bn), AGR (%), 2011-2015

Table 13: Lucentis, Eylea and Avastin Comparison of Reported Characteristics

Table 14: Lucentis Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 15: Lucentis Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 16: Avastin Historical Revenue ($bn), AGR (%), 2011-2015

Table 17: Avastin Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 18: Avastin Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 19: Visudyne Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 20: Visudyne Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 21: Jetrea Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 22: Jetrea Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 23: Dry AMD Segment Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 24: Dry AMD Segment Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 25: DR Segment Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 26: DR Segment Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 27: World AMD and Other Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 28: World AMD and Other Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 29: Market Breakdown by Disease Segment Revenue ($bn), Market Share (%), 2015

Table 30: Retinal Diseases Market Forecasts by Segment Revenue ($bn), Market Share (%) for 2015, 2020 and 2026

Table 31: Retinal Diseases Market Forecasts by Segment Revenues ($bn), AGR (%), CAGR (%), 2015-2026

Table 32: Market Breakdown by Products Market Share (%), 2015

Table 33: The National Market Breakdown by Revenue ($bn) and Market Share (%), 2015

Table 34: Regional Market Breakdown Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2026

Table 35: US Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 36: US Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 37: Japan Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 38: Japan Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 39: EU5 Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2026

Table 40: Germany Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 41: Germany Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 42: France Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 43: France Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 44: Italy Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 45: Italy Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 46: UK Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 47: UK Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 48: Spain Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2015-2020

Table 49: Spain Retinal Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2020-2026

Table 50: BRIC Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2026

Table 51: China Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2020

Table 52: China Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2020-2026

Table 53: India Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2020

Table 54: India Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2020-2026

Table 55: Brazil Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2020

Table 56: Brazil Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2020-2026

Table 57: Russia Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2015-2020

Table 58: Russia Retinal Diseases Market Forecast Revenue ($bn), AGR (%) and CAGR (%), 2020-2026

Table 59: Selected R&D Wet AMD Pipeline, 2015

Table 60: Selected R&D Dry AMD Pipeline, 2015

Table 61: Selected R&D Diabetic Retinopathy Pipeline, 2015

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

LIST OF COMPANIES AND ORGANISATION 

Abbott

Acucela

Alcon

Aldexa

Alimera Sciences

Alkeus Pharmaceuticals

Allegro

Allergan

Allergan and Molecular Partners

Ampio Pharmaceuticals

Association for Research in Vision and Ophthalmology

Avalanche Biotechnologies

Bayer Healthcare

Biotime

Biovail Corporation

Bristol-Myers Squibb

Casey Eye Institute

Chengdu Kanghong Biotech

Colby Pharmaceutical

Columbia University

CoMentis

Eli Lilly

EyeGate Pharmaceuticals

Eyetech

FDA

ForSight Vision4

Genentech

Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

GlaxoSmithKline (GSK)

iCo Therapeutics

Icon Bioscience

International Diabetes Federation

Italian Competition Authority (ICA)

Japanese Ministry of Health, Labour and Welfare

Lpath, Inc.

MacuCLEAR

Mesoblast

MSD

Neuron Systems Inc.

Neurotech

NHS

NICE

Novartis

Novo Nordisk

Ocata Therapeutics

OHR Pharmaceutical

Ophthotec Corporation

Ora Bio

Oregon Health and Science University

Othera Pharmaceuticals

Oxford BioMedica

Oxigene

PanOptica

Pfizer

QLT

Regeneron

ReVision Therapeutics

Roche

Santen Pharmaceutical

Sirion Therapeutics

StemCells

Stemedica Cell Technologies

ThromboGenics

Tyrogenex

UCB

UK's General Medical Council

University College London (UCL)

US National Eye Institute

Valeant Pharmaceuticals

Varinel

VisionCare Ophthalmic Technologies

Vitreoretinal Technologies

WHO

Xcovery Group

Xcovery Vision

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

SOURCE Visiongain Ltd